John K Clarke - Net Worth and Insider Trading
John K Clarke Net Worth
The estimated net worth of John K Clarke is at least $7 Million dollars as of 2024-11-10. John K Clarke is the Director of Momenta Pharmaceuticals Inc and owns about 69,123 shares of Momenta Pharmaceuticals Inc (MNTA) stock worth over $4 Million. John K Clarke is the Director of Alnylam Pharmaceuticals Inc and owns about 8,891 shares of Alnylam Pharmaceuticals Inc (ALNY) stock worth over $2 Million. John K Clarke is also the Director of Verastem Inc and owns about 194,093 shares of Verastem Inc (VSTM) stock worth over $766,667. Besides these, John K Clarke also holds aTyr Pharma Inc (ATYR) . Details can be seen in John K Clarke's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that John K Clarke has not made any transactions after 2021-05-21 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of John K Clarke
John K Clarke Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, John K Clarke owns 5 companies in total, including aTyr Pharma Inc (ATYR) , Alnylam Pharmaceuticals Inc (ALNY) , and Momenta Pharmaceuticals Inc (MNTA) among others .
Click here to see the complete history of John K Clarke’s form 4 insider trades.
Insider Ownership Summary of John K Clarke
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ATYR | aTyr Pharma Inc | 2021-05-21 | director |
| ALNY | Alnylam Pharmaceuticals Inc | 2018-05-31 | director |
| MNTA | Momenta Pharmaceuticals Inc | 2015-06-10 | director |
 | | 2013-06-12 | director |
| | 2007-09-25 | 10 percent owner |
John K Clarke Latest Holdings Summary
John K Clarke currently owns a total of 4 stocks. Among these stocks, John K Clarke owns 69,123 shares of Momenta Pharmaceuticals Inc (MNTA) as of May 12, 2015, with a value of $4 Million and a weighting of 50.23%. John K Clarke owns 8,891 shares of Alnylam Pharmaceuticals Inc (ALNY) as of May 31, 2018, with a value of $2 Million and a weighting of 34.16%. John K Clarke also owns 194,093 shares of Verastem Inc (VSTM) as of June 12, 2013, with a value of $766,667 and a weighting of 10.62%. The other 1 stocks aTyr Pharma Inc (ATYR) have a combined weighting of 4.99% among all his current holdings.
Latest Holdings of John K Clarke
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| MNTA | Momenta Pharmaceuticals Inc | 2015-05-12 | 69,123 | 52.48 | 3,627,575 |
| ALNY | Alnylam Pharmaceuticals Inc | 2018-05-31 | 8,891 | 277.43 | 2,466,630 |
| VSTM | Verastem Inc | 2013-06-12 | 194,093 | 3.95 | 766,667 |
| ATYR | aTyr Pharma Inc | 2021-05-21 | 115,575 | 3.12 | 360,594 |
Holding Weightings of John K Clarke
John K Clarke Form 4 Trading Tracker
According to the SEC Form 4 filings, John K Clarke has made a total of 0 transactions in Momenta Pharmaceuticals Inc (MNTA) over the past 5 years. The most-recent trade in Momenta Pharmaceuticals Inc is the sale of 38,400 shares on May 12, 2015, which brought John K Clarke around $766,464.
According to the SEC Form 4 filings, John K Clarke has made a total of 0 transactions in Alnylam Pharmaceuticals Inc (ALNY) over the past 5 years. The most-recent trade in Alnylam Pharmaceuticals Inc is the sale of 15,000 shares on May 31, 2018, which brought John K Clarke around $2 Million.
According to the SEC Form 4 filings, John K Clarke has made a total of 0 transactions in Verastem Inc (VSTM) over the past 5 years. The most-recent trade in Verastem Inc is the acquisition of 1,931 shares on June 12, 2013, which cost John K Clarke around $222,442.
More details on John K Clarke's insider transactions can be found in the Insider Trading History of John K Clarke table.Insider Trading History of John K Clarke
- 1
John K Clarke Trading Performance
GuruFocus tracks the stock performance after each of John K Clarke's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John K Clarke is 34.03%. GuruFocus also compares John K Clarke's trading performance to market benchmark return within the same time period. The performance of stocks bought by John K Clarke within 3 months outperforms 8 times out of 10 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how John K Clarke's insider trading performs compared to the benchmark.
Performance of John K Clarke
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 18.23 | | | | | |
| Relative Return to S&P 500(%) | 16.85 | | | | | |
John K Clarke Ownership Network
Ownership Network List of John K Clarke
Ownership Network Relation of John K Clarke
John K Clarke Owned Company Details
What does aTyr Pharma Inc do?
Who are the key executives at aTyr Pharma Inc?
John K Clarke is the director of aTyr Pharma Inc. Other key executives at aTyr Pharma Inc include Chief Financial Officer Jill Marie Broadfoot , Chief Medical Officer Sanjay Shukla , and See Remarks Nancy Krueger .
aTyr Pharma Inc (ATYR) Insider Trades Summary
Over the past 18 months, John K Clarke made no insider transaction in aTyr Pharma Inc (ATYR). Other recent insider transactions involving aTyr Pharma Inc (ATYR) include a net purchase of 65,000 shares made by Sanjay Shukla , a net purchase of 3,410 shares made by Jill Marie Broadfoot , and a net purchase of 100,000 shares made by Paul Schimmel .
In summary, during the past 3 months, insiders sold 0 shares of aTyr Pharma Inc (ATYR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,590 shares of aTyr Pharma Inc (ATYR) were sold and 225,000 shares were bought by its insiders, resulting in a net purchase of 223,410 shares.
aTyr Pharma Inc (ATYR)'s detailed insider trading history can be found in Insider Trading Tracker table.
aTyr Pharma Inc Insider Transactions
John K Clarke Mailing Address
Above is the net worth, insider trading, and ownership report for John K Clarke. You might contact John K Clarke via mailing address: C/o Cardinal Health Partners, 221 Nassau Street, Princeton Nj 08542.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
